ARGX-121

January 12, 2026 — argenx SE (Euronext & Nasdaq: ARGX) reported preliminary, unaudited 2025 global product net sales of approximately $4.15 billion (+90% YoY), including ~$1.29 billion in Q4 2025, and outlined 2026 strategic priorities centered on expanding impact of its FcRn inhibitor franchise led by VYVGART (efgartigimod).

The company stated VYVGART is being used by ~19,000 patients globally across approved indications (gMG, CIDP; and primary ITP in Japan). argenx has submitted an sBLA for VYVGART IV in AChR-antibody–negative gMG (MuSK+, LRP4+, and triple seronegative); if approved, it expects a launch by end-2026. Planned/expected data include Phase 3 topline results for ocular MG (ADAPT OCULUS) in Q1 2026, primary ITP (ADVANCE-NEXT) in Q4 2026, and myositis (ALKIVIA) in Q3 2026.

Pipeline/business updates: four registrational readouts are expected in 2026 (including first for empasiprubart, anti-C2), three new molecules are expected to enter Phase 1 in 2026, and leadership changes (COO Karen Massey to CEO) are proposed for shareholder approval on May 6, 2026.